Short-term results of a pulsed therapy with hydrocortisone eye drops to treat moderate to severe dry eye in primary Sjögren syndrome patients.

Abstract

We investigated the safety and efficacy of short-term treatment with topical low-dose hydrocortisone sodium phosphate 0.335% (PFH) in patients with moderate to severe primary Sjögren syndrome (SS)-related dry eye disease (DED). A retrospective single-centre interventional study. All patients received PFH for 6days with a pulsed posology: three times daily for 2days, twice daily for 2days, and once daily for 2days. This scheme was repeated for 3 consecutive months and then alternated for 3months. Data were collected at baseline, 3months, and 6months of follow-up. A total of 40 SS patients were enrolled. Conjunctival hyperaemia and corneal-conjunctival stain significantly improved (p < 0.001). Ocular Surface Disease Index score reduced significantly between baseline and 3months and between baseline and 6months (p < 0.001). The tear film osmolarity lowered significantly in each eye from baseline to 3months and from baseline to 6months (p = 0.002 and p = 0.037, respectively). Comparing results at 3 and 6months, the Ocular Surface Disease Index score (p = 1.000), the frequency of lacrimal substitutes installation (p = 0.632), and tear film osmolarity (right eye p = 0.518, left eye p = 1.000) did not change significantly. Intraocular pressure did not change during the study period. PFH eye drops with a pulsed posology improve signs and symptoms, not affecting the intraocular pressure in SS-related DED. Therefore, this pulsed treatment is safe and efficacious.